168 related articles for article (PubMed ID: 2292530)
21. Cefpodoxime pharmacokinetics in children: effect of food.
Kearns GL; Abdel-Rahman SM; Jacobs RF; Wells TG; Borin MT
Pediatr Infect Dis J; 1998 Sep; 17(9):799-804. PubMed ID: 9779765
[TBL] [Abstract][Full Text] [Related]
22. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
Stevens DL; Pien F; Drehobl M
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
[TBL] [Abstract][Full Text] [Related]
23. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.
Kumar V; Madabushi R; Lucchesi MB; Derendorf H
J Vet Pharmacol Ther; 2011 Apr; 34(2):130-5. PubMed ID: 21395603
[TBL] [Abstract][Full Text] [Related]
25. Human skin disposition of cefpodoxime after oral administration of its proxetil ester.
Zolfino I; Senesi S; Campa M; Di Vito A; Mosca F; Favini P; Ducci M; Danesi R; Del Tacca M
J Antimicrob Chemother; 1992 Nov; 30(5):731-3. PubMed ID: 1493994
[No Abstract] [Full Text] [Related]
26. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution.
Borin MT; Forbes KK; Hughes GS
Biopharm Drug Dispos; 1995 May; 16(4):295-302. PubMed ID: 7548778
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
[TBL] [Abstract][Full Text] [Related]
28. Effect of timing of food on absorption of cefpodoxime proxetil.
Borin MT; Driver MR; Forbes KK
J Clin Pharmacol; 1995 May; 35(5):505-9. PubMed ID: 7657851
[TBL] [Abstract][Full Text] [Related]
29. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.
Höffler D; Koeppe P; Corcilius M; Przyklinik A
Infection; 1990; 18(3):157-62. PubMed ID: 2365467
[TBL] [Abstract][Full Text] [Related]
30. Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.
Takasugi N; Tsunaga N; Sugino N; Numa F; Kato H
Antimicrob Agents Chemother; 1996 Aug; 40(8):1832-4. PubMed ID: 8843289
[TBL] [Abstract][Full Text] [Related]
31. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. The Cefpodoxime Pharyngitis Study Group.
Brown RJ; Batts DH; Hughes GS; Greenwald CA
Clin Ther; 1991; 13(5):579-88. PubMed ID: 1799915
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
Zuck P; Rio Y; Ichou F
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():71-7. PubMed ID: 2292534
[TBL] [Abstract][Full Text] [Related]
33. Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil.
Totsuka K; Shimizu K; Mori N; Sugihara T; Sakai A; Yamaji S; Michisuji Y; Shinohara Y; Kubo A; Tokuoka H
Int J Antimicrob Agents; 2001 Nov; 18(5):463-9. PubMed ID: 11711262
[TBL] [Abstract][Full Text] [Related]
34. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
Hughes GS; Heald DL; Barker KB; Patel RK; Spillers CR; Watts KC; Batts DH; Euler AR
Clin Pharmacol Ther; 1989 Dec; 46(6):674-85. PubMed ID: 2557183
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
[TBL] [Abstract][Full Text] [Related]
36. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue.
Naber KG; Kinzig M; Adam D; Sörgel F; Bajorski AH; Kiehn R
Infection; 1991; 19(1):30-5. PubMed ID: 1707399
[TBL] [Abstract][Full Text] [Related]
37. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Geddes AM
Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
[TBL] [Abstract][Full Text] [Related]
38. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients.
Backhouse C; Wade A; Williamson P; Tremblay D; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():29-34. PubMed ID: 2292527
[TBL] [Abstract][Full Text] [Related]
39. Microbiological evaluation of cefpodoxime proxetil.
Wiedemann B; Luhmer E; Zühlsdorf MT
Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets.
Abdel-Rahman SM; Maxson S; Teo C; Hubbard AE; Kearns GL
J Clin Pharmacol; 2000 Mar; 40(3):290-5. PubMed ID: 10709158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
